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 INTRODUCTION 
 
Background, Significance, and Motivation 
 
Pancreatic cancer is predicted to become the second leading cause of cancer-related death in the 
United States before 2030, despite the fact that it currently accounts for merely 3% of all cancer 
cases (Rahib et al., 2014) (Cancer.org, 2018). Currently, there is no one standard method for 
early detection of this deadly disease, and researchers are unsatisfied with the performance of 
current biomarkers in the detection of the most prominent form of pancreatic cancer: pancreatic 
ductal adenocarcinoma, or PDAC for short (​Bhat et al., 2012​). The most widely used PDAC 
biomarker is CA 19-9 --the only biomarker currently approved by the FDA (​Partyka et al., 2012)​. 
By itself, CA 19-9 is unsuitable for clinical diagnosis, but it promises to be useful in combination 
with other diagnostic tests (Wu et al., 2013) (Herreros-Villanueva et al., 2016). Despite its 
shortcomings, it is currently unsurpassed by any other biomarker in terms of sensitivity and 
specificity (Herreros-Villanueva et al., 2016). 
 
Biomarker detection methods are largely dependent on the use of antibodies (Chang et al, 2017). 
The immune system naturally produces these large proteins which form strong and specific 
bonds to the epitopes of their target antigen in order to destroy foreign particles (​Lipman et al​, 
2008). (American Cancer Society, 2015). Scientists have manipulated this characteristic to create 
a wide range of diagnostic and therapeutic tools (​Lipman et al.​, 2008).  
 
  
Figure 1. The interactions between an antibody and its target epitope on an antigen (Campbell, 2008). 
   
 
CA 19-9 antibodies bind to a sugar epitope, rather than a protein (​Partyka et al., 2012​). 
Clinically, only a very small number of carbohydrate antigens are used as biomarkers, as 
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 expression levels are difficult to reliably measure due to lack understanding of peptide-sugar 
interactions (​Manimala et al., 2007​).  
 
While a CA-19-9 blood assay is currently the best biomarker-based cancer detection approach in 
terms of sensitivity and specificity, it is based on the use of monoclonal antibodies, or mAbs 
(​Herreros-Villanueva et al., 2016​). Monoclonal antibodies are expensive, in part due to their long 
production timelines, and are produced using ethically problematic methods (​Lipman et al., 
2005​). However, synthetic antibodies appear to be a favorable alternative, as they are able to 
circumvent many of the shortcomings of mAbs while preserving comparable function (Wals et 
al., 2014).  
 
Therefore, sugar-peptide interactions will be investigated in order to develop a “molecular 
missile” for the detection of sugars --that is, a macromolecule that directs itself towards strong 
binding to its corresponding target. By developing this synthetic antibody in E. coli and 
incorporating the unnatural amino acid L-DOPA, this design will to bypass the drawbacks of 
monoclonal antibodies and design a model for the creation of functional antibodies with the 
ability to target sugar biomarkers in countless other cancers and diseases.  
 
Literature Review and Critiques of Current Technology  
 
Monoclonal and Polyclonal Antibodies  
 
Determining the levels of CA-19-9 in the blood is currently the best biomarker-based PDAC 
detection approach in terms of sensitivity and specificity; however, it depends on the use of 
monoclonal antibodies (​Herreros-Villanueva et al., 2016)​. ​Although many different anti-CA 19-9 
mAbs have been developed, the lack of optimization of these mAbs has resulted in unsatisfactory 
specificity for sialyl-Lewis (​Partyka et al., 2012)​.​ Monoclonal antibodies inherently have several 
unresolved issues stemming from their method of production: they are 1) expensive, 2) take a 
long time to produce, and are 3) ethically problematic (Siddiqui et al., 2010). 
 
The hybridoma method (Figure 2) is the predominant method of mAb production (​Leenaars et 
al., 2015).​ This method creates an antibody library through trial and error and revolves around 
injecting animals with the target antigen to stimulate natural antibody production (​Leenaars et 
al., 2015).​ However, exploiting an animal’s immune system by intentionally infecting them with 
a disease is an ethically questionable practice. Additionally, producing mAbs with the hybridoma 
method is an expensive pursuit, due to the use of animals and months to years required for 
success (​Leenaars et al., 2015)​. 
 
2 
  
Figure 2. Traditional hybridoma method for monoclonal antibody production (Michnick, 2008). 
 
In contrast, polyclonal antibodies (pAbs) require less time, money, and technical skill to create 
while maintaining the specificity possessed by monoclonal antibodies (​Lipman et al., 2005​). 
However, batch-to-batch variability is a concern in pAbs since it requires the used of multiple 
animals at different times (​Lipman et al., 2005​). Additionally, the ethical issues of mAbs are still 
unresolved in pAbs (​Lipman et al., 2005​). 
 
Nevertheless, mAbs and pAbs are unparalleled in terms of affinity and specificity (Siddiqui et 
al., 2010). Therefore, this project will aim to meet the unmatched performances of mAbs and 
pAbs while designing a novel system to overcome their pitfalls and ethical problems via 
synthetic antibodies.  
 
Synthetic Antibodies 
 
Synthetic antibodies for diagnostics engineered to replicate the modularity and versatility of 
natural immunoglobulins (Deyev et al, 2009). These synthetic proteins are typically developed 
based on the findings of biochemical investigations focused on protein-protein interactions and 
can be easily manipulated and mass-produced at a low cost (Umeda et al, 2010). However, at 
their current stage of development, they are unsuitable for diagnostic applications due to their 
relatively low levels of affinity, selectivity, and efficiency (Umeda et al, 2010). Some types of 
synthetic antibodies bind to their target antigen via free-radical based reactions, however, this 
strategy tends to produce chemically heterogeneous mixtures of cross-linked peptides that 
convolute detection (​Denison, 2004)​. 
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 Unnatural Amino Acids  
 
However, a more recent development in the field bioengineering that has allowed the potential of 
synthetic antibodies to skyrocket is the development of unnatural amino acids capable of being 
incorporated into recombinant proteins synthesized in Escherichia coli, or E. coli (Lital et al., 
2003). These unnatural amino acids replicate the structure of post-translationally modified amino 
acids, and with continual development, this technology has the potential to render obsolete one 
of the biggest drawbacks to using E. coli in synthetic biology --the inability of E. coli to perform 
post-translational modifications.  
 
Before an unnatural amino acid can be incorporated into a peptide, an unnatural tRNA and tRNA 
synthetase must be introduced into the cell manufacturing the peptide through a vector, such as a 
plasmid (Wals et al., 2014). The unnatural tRNA is typically designed so that the amber stop 
codon (TAG/UAG) signals for the incorporation of this unnatural tRNA when mRNA is 
translated in the cell (Wals et al., 2014). Of the three stop codons found in nature, the amber stop 
codon used the least frequently in E. coli --only 7% of the time (Wals et al., 2014) Since it is 
rarely used in essential proteins, using this stop codon minimizes the possibility of killing the cell 
or severely disrupting function as an unintended side effect of unnatural amino acid 
incorporation (Wals et. al, 2014). 
 
Specifically, the work done by Umeda et al in the site-specific incorporation a redox-active 
amino acid 3,4-dihydroxy-L-phenylalanine (l-DOPA) is of particular usefulness in the 
development of synthetic antibodies (Umeda et al., 2010). This synthetic antibody rectifies the 
issue of weak binding affinities of synthetic antibodies by supplementing the peptide interactions 
with the target antigen with an irreversible covalent bond. See Figure 3 below for the mechanism 
of its function.  
 
   
Figure 3. Mechanism of l-DOPA covalent bond formation. The peptide (red molecule) binds to 
the antigen (blue molecule).  Figure adapted from Umeda et al (2010). 
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While several papers have demonstrated the utility of l-DOPA incorporation for strengthening 
both protein-protein (Umeda et al., 2009) and peptide-protein bonds (Umeda et al., 2010), 
researchers have yet to use l-DOPA to strengthen the bond between peptide-carbohydrate 
interactions. However, upon analyzing the structure of carbohydrates the mechanism of l-DOPA 
in strengthening protein-peptide interactions, its success in this application appears to be likely. 
The nucleophilic hydroxyl groups that are characteristically plentiful in carbohydrate structures 
will provide l-DOPA many potential locations for covalent bond formation. 
 
The pAC-DHPheRS-6TRN plasmid, which codes for l-DOPA tRNA and tRNA synthetase, has 
already been used in previous senior design projects, and it will be used in this project as well 
(Therriault et al. 2016) (Nguyen et al., 2017). With this plasmid, the amber stop codon will 
signal for the incorporation of l-DOPA (Therriault et al., 2016).  
 
This ability to mimic post-translational modifications with unnatural amino acids is significant, 
as using E. coli for recombinant protein production has many advantages. E. coli’s doubling time 
is only 20 minutes, which is must faster than other cell type options such as yeast, insect, or 
mammalian cells, which all have a doubling time on the range of hours or even days (​Rosano et 
al., 2014) (Murakami et al., 2009) ​(Thermo Fisher Scientific, 2017) (Sitton et al., 2008). E. coli 
is also favorable due to a simple lab setup, cheap growth media, ease of transformation, and 
those using this cell type also avoid the ethical issues that arise when using animals to produce 
recombinant proteins (​Rosano, 2014)​. While recombinant proteins produced by E. coli are more 
susceptible to genetic mutations, minimizing the length of the peptide used in the design will 
allow for DNA sequencing to be used to check for these potential spontaneous mutations (Wals, 
2014).  
 
Project Objectives 
 
The overall goal of this project is to create a proof-of-concept model for designing a synthetic 
antibody capable of binding to sugars by developing a synthetic antibody for CA 19-9 detection 
in PDAC. In targeting a sugar, this project aims to provide insight into a relatively 
under-researched domain. In using synthetic monoclonal peptides, the benefits of monoclonal 
antibodies will be maintained while circumventing the cost-effective and ethical drawbacks of 
such manufacturing. 
 
The main components of the proposed synthetic antibody are outlined in Figure 4 below.  
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Figure 4. Diagram of synthetic antibody design. Not to scale. 
 
The peptide sequence will be responsible for binding to the epitope of the biomarker, the 
l-DOPA will strengthen the ability of the peptide to bind to the biomarker, the GFP segment will 
serve as a fluorescent reporter, and the 6-His tag facilitates the protein purification process. This 
is based on the modular design presented in Umeda et al (Umeda et al., 2010), which has been 
used in previous senior design projects as well (Therriault et al., 2016) (Nguyen et al., 2017). 
 
Project Milestones and Expected Results 
 
The first milestone for this project is identifying a target biomarker. CA 19-9 was chosen as the 
target biomarker based on its high specificity and sensitivity to PDAC, particularly in 
comparison to other proposed biomarkers. Since CA 19-9 is a carbohydrate, a parallel objective 
of the project is to elucidate peptide-sugar interactions.  
 
The second milestone is identifying a peptide sequence that will facilitate binding to the target 
antigen through a bioinformatics study. This involves pinpointing monomeric proteins that bind 
to CA 19-9’s epitope sialyl-Lewis a, and selecting a protein to base the peptide sequence off of 
with the aim of minimizing the length of the peptide sequence required for binding.  
 
The third milestone is designing the plasmid for vector insertion into E. coli. This plasmid 
includes the DNA sequence corresponding to the amino acid sequence of the synthetic antibody 
as diagrammed in Figure 4. The E. coli will translate the DNA sequence contained in this 
plasmid to manufacture this synthetic antibody. 
 
Backup plan 
 
If L-DOPA does not strengthen antibody affinity as expected, the target biomarker will be 
6 
 switched from a carbohydrate to a protein, as l-DOPA been already proven to enhance 
peptide-protein bonds (Umeda et al., 2010). 
 
Significance 
 
The development of a proof-of-concept model for a synthetic antibody capable of binding to 
sugars will not only benefit the scientific community at large, but also the field of medicine. This 
accomplishment will help expand the knowledge of peptide-sugar interactions of the scientific 
community, a domain that is markedly under-researched. This specific project can help the CA 
19-9 blood test become cheaper and more widely-available to PDAC patients, thereby increasing 
future possibilities for early detection in more patients, and consequently improving overall 
PDAC survival outlooks (Berquist et al., 2016).  
 
However, the potential benefits for the medical field do not stop here. By modularizing the 
design of synthetic antibodies capable of binding strongly with sugars, this project can greatly 
expand the diagnostic and therapeutic applications of antibodies in an ethical manner. With this 
development, a whole new category of antigens can now be targeted. The GFP reporter molecule 
included in this design can be theoretically swapped for a therapeutic payload, equipping the 
antibody to be used in targeted drug deliveries and other therapies.  
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 PEPTIDE SEQUENCE DESIGN 
 
Introduction 
By performing a bioinformatics study, I determined the peptide sequence for the portion of the 
synthetic antibody that will be responsible for creating a bond with the CA 19-9 epitope sialyl 
Lewis. This bond will be strengthened with l-DOPA. The DNA sequence that codes for this 
amino acid sequence will be inserted into an experimental plasmid in order to engineer E. coli to 
synthesize the molecular missile, which targets CA 19-9. The other components of this 
molecular missile, namely l-DOPA, the GFP reporting molecule, and the His tag are all 
well-defined structures with predetermined peptide sequences.  
 
Design Constraints 
The peptide sequence chosen will have to be proven to selectively bind to sialyl Lewis a. 
Specific binding would be optimal, but an unrealistic goal considering the limited amount of 
research on this topic. Future work could use peptide library creation and directed evolution to 
make the proposed synthetic antibody specific. The peptide sequence also must be able to be 
expressed in E. coli, the chosen cell type for recombinant protein production. Additionally, the 
peptide sequence must be a functional monomeric protein, as multimeric proteins are too 
complicated to express in E. coli given the laboratory resources available to SCU students. 
 
There are also different limitations regarding the length of the chosen peptide sequence. Realistic 
technical capabilities include either (1) going to a company to synthesize the vector, (2) piecing 
together two short oligos using a Klenow reaction, or (3) using high-fidelity PCR to amplify a 
fragment of DNA from a plasmid. The first option grants the most flexibility in both length and 
customizability, but it is an expensive option. For the second option, the corresponding DNA 
sequence is limited to one’s imagination, so long as it is very short, ideally less than roughly 20 
amino acids long. If the peptide sequence is longer, the last option is the most favorable, 
however, the corresponding DNA sequence is limited to those included in commercially 
available plasmids.  
 
Methodology Constraints 
This bioinformatics search is limited to what information is available for free through online 
search engines and the SCU library database.  
 
Back-Up Plan 
If the bioinformatics search for a suitable peptide sequence is unsuccessful, the target antigen 
will have to be switched to a biomarker whose binding patterns are more thoroughly researched 
than CA 19-9. 
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 Results 
After a thorough search on several SCU library databases, including ​SciFinder​, I found a 1998 
paper by Torgersen et al that described a short (44 amino acids) peptide sequence that was 
proven to bind to sialyl-Lewis x, a close relative of the target antigen sialyl-Lewis a. While the 
authors of the paper did not test the ability of the peptide sequence to bind to sialyl-Lewis a 
themselves, the peptide sequence they expressed in E. coli did contain the binding regions 
required for binding to sialyl-Lewis a, as described in a 2008 paper by Veluraja, et al. As 
illustrated in Figure 5 below, these “hotspots” include Tyr94, Arg97, Glu98, Lys99, Asp100, and 
Lys111 (Veluraja, et al., 2008). 
 
Figure 5. E-selectin binding to sialyl-Lewis a. Both essential and non-essential interactions are 
shown. Figure adapted from Veluraja, et al​. 
 
Discussion 
Replicating the mutated MBP (mannose-binding protein) peptide fragment as described in a 
1998 paper authored by Torgersen et al (Figure 6) initially seems to be a desirable option. This 
mutated MBP peptide fragment contains domains from another protein, E-selectin, that are 
important to binding to the CA 19-9 epitope. E-selectin is a protein that​ interacts with 
sialyl-Lewis a, among other ligands, to trigger an immune response (Mann et al., 2011). ​Given 
that this peptide fragment contains the “hotspots” needed for binding to sialyl-Lewis a, one can 
reasonably hypothesize that the given fragment will be able to also bind to sialyl-Lewis a in 
addition to sialyl-Lewis x. Fine-tuning of the fragment through iterative experimentation would 
need to be done before specific binding to sialyl-Lewis a could be accomplished, but the 
selectivity of this relatively short amino acid sequence is suitable for this project’s prototypic 
goals. 
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Figure 6. Aligned amino acid sequences from relevant fragments of MBP and E-selectin. Yellow 
boxes indicate the locations where MBP-A was mutated to contain the corresponding E-selectin 
sequence, which is boxed in red. Adapted from Torgersen et al.  
 
This fragment is a favorable choice as the aforementioned paper demonstrated that it possesses 
binding capabilities suitable for selectively targeting sialyl Lewis a and can be successfully 
expressed in E. coli. However, the 44 amino acid length of the fragment meant that the required 
DNA fragment length (132 bp) would be much too long to be created using DNA oligo 
synthesis. Although high-fidelity DNA polymerase could be used to amplify the DNA sequence 
that encodes this protein fragment from a plasmid for insertion into the experimental plasmid, 
there is not commercially available plasmid that contains the mutated MBP peptide as described 
in Torgersen et al. 
 
However, it is possible to procure a plasmid that contains the entire sequence for E-selectin, 
including the binding domain the mutated MBP protein was designed to mimic. This sequence is 
43 amino acids long and is boxed in red in Figure 6 above. Although this option is not as 
preferable, as the expression of E-selectin in E. coli has proven to be rather difficult, studies have 
shown that it is possible to express fragments of E-selectin in E. coli (Kuwano, 2013). A plasmid 
that contains the entire E-selectin sequence capable of E. coli expression, such as 
pGL3-ELAM-luc can be used to obtain the corresponding DNA sequence to be inserted into the 
experimental vector.  
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 The final vector design is depicted Figure 6 below: 
 
Figure 6. Plasmid map of the experimental vector. Image generated by Epoch Life Science, Inc. 
 
In this design, the DNA sequence that codes for E-selectin fragment will be directly followed by 
the amber stop codon (TAG), which will be immediately followed by the DNA sequence for 
EGFP, which is followed by the DNA sequence for the 6-His tag. 
 
Conclusion 
The design peptide sequence responsible for binding to CA 19-9 will consist of the 43 amino 
acid-long sequence as boxed in red in Figure 6. This proposed design meets the requirements set 
forth by the “Design Constraints” section of this chapter. The chosen sequence selectively binds 
to the epitope of CA 19-9 in a monomeric form. Research is supportive of the feasibility of 
expression in E. coli. This design can be manufactured in a couple of ways. The vector design 
can be sent to a company for production, or the DNA sequence that encodes this selected peptide 
fragment can also be obtained by performing high-fidelity PCR on pGL3-ELAM-luc, using the 
appropriate forward and reverse primers. Using the appropriate restriction enzymes, the DNA 
sequence can then be inserted into the vector pET28b-P1+TAG+GFP+His, which contains code 
for rest of the design. 
 
Acknowledgments: 
I would like to recognize Esther Bartlett for her contributions to this research project. 
11 
 BIBLIOGRAPHY 
Alfonta, L., Zhang, Z., Uryu, S., Loo, J., & Schultz, P. (2003). Site-Specific Incorporation 
of a Redox-Active Amino Acid into Proteins. ​Journal Of The American Chemical 
Society​, ​125​(48), 14662-14663. http://dx.doi.org/10.1021/ja038242x 
Bhat, K., Wang, F., Ma, Q., Li, Q., Mallik, S., Hsieh, T., & Wu, E. (2012). Advances in 
Biomarker Research for Pancreatic Cancer. ​Current Pharmaceutical Design​, ​18​(17), 
2439-2451. http://dx.doi.org/10.2174/13816128112092439 
Campbell, N. (2008). ​Biology.​ (8th ed.). Pearson. 
Chang, J., & Kundranda, M. (2017). Novel Diagnostic and Predictive Biomarkers in 
Pancreatic Adenocarcinoma. ​International Journal Of Molecular Sciences​, ​18​(3), 667. 
http://dx.doi.org/10.3390/ijms18030667 
Denison, C. (2004). Toward a General Chemical Method for Rapidly Mapping 
Multi-Protein Complexes. ​Journal Of Proteome Research​, ​3​(3), 417-425. 
http://dx.doi.org/10.1021/pr034071j 
Deyev, S., & Lebedenko, E. (2009). Modern Technologies for Creating Synthetic 
Antibodies for Clinical application. ​Acta Naturae​, ​1​(1), 32-50. 
        “Growth and Maintenance of insect cell lines: User Guide.” ThermoFisher Scientific, 2017.  
Herreros-Villanueva, M., & Bujanda, L. (2016). Non-invasive biomarkers in pancreatic 
cancer diagnosis: what we need versus what we have. ​Annals Of Translational 
Medicine​, ​4​(7), 134-134. http://dx.doi.org/10.21037/atm.2016.03.44 
Key Statistics for Pancreatic Cancer​. (2018). ​Cancer.org​. Retrieved 20 April 2018, from 
https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html 
Kawano, S., Iyaguchi, D., Okada, C., Sasaki, Y., & Toyota, E. (2013). Expression, 
Purification, and Refolding of Active Recombinant Human E-selectin Lectin and EGF 
Domains in Escherichia coli. ​The Protein Journal​, ​32​(5), 386-391. 
http://dx.doi.org/10.1007/s10930-013-9496-z 
Leenaars, M., & Hendriksen, C. (2005). Critical Steps in the Production of Polyclonal and 
Monoclonal Antibodies: Evaluation and Recommendations. ​ILAR Journal​, ​46​(3), 
269-279. http://dx.doi.org/10.1093/ilar.46.3.269 
Lipman, N., Jackson, L., Trudel, L., & Weis-Garcia, F. (2005). Monoclonal Versus 
Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information 
Resources. ​ILAR Journal​, ​46​(3), 258-268. http://dx.doi.org/10.1093/ilar.46.3.258 
Manimala, J., Roach, T., Li, Z., & Gildersleeve, J. (2007). High-throughput carbohydrate 
microarray profiling of 27 antibodies demonstrates widespread specificity problems. 
Glycobiology​, ​17​(8), 17C-23C. http://dx.doi.org/10.1093/glycob/cwm047 
12 
 Mann, A., & Tanaka, T. (2012). E-selectin: Its Role in Cancer and Potential as a Biomarker. 
Translational Medicine​, ​01​(S1). http://dx.doi.org/10.4172/2161-1025.s1-002 
Michnick, S., & Sidhu, S. (2008). Submitting antibodies to binding arbitration. ​Nature 
Chemical Biology​, ​4​(6), 326-329. http://dx.doi.org/10.1038/nchembio0608-326 
Murakami, C., & Kaeberlein, M. (2009). Quantifying Yeast Chronological Life Span by 
Outgrowth of Aged Cells. ​Journal Of Visualized Experiments​, (27). 
http://dx.doi.org/10.3791/1156 
Nimse, S., Sonawane, M., Song, K., & Kim, T. (2016). Biomarker detection technologies 
and future directions. ​The Analyst​, ​141​(3), 740-755. 
http://dx.doi.org/10.1039/c5an01790d 
        Nguyen, T., Kiyohara, C., & Batiuk, E. (2017).  “Engineering Synthetic Antibody by  
                Expanded Genetic Code.” ​Bioengineering Senior Theses.​ 60. 
 
Partyka, K., Maupin, K., Brand, R., & Haab, B. (2012). Diverse monoclonal antibodies 
against the CA 19-9 antigen show variation in binding specificity with consequences 
for clinical interpretation. ​Proteonomics​, ​12​(13), 2212-2220. 
http://dx.doi.org/10.1002/pmic.201100676 
Rahib, L., Smith, B., Aizenberg, R., Rosenzweig, A., Fleshman, J., & Matrisian, L. (2014). 
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, 
Liver, and Pancreas Cancers in the United States. ​Cancer Research​, ​74​(11), 2913-2921. 
http://dx.doi.org/10.1158/0008-5472.can-14-0155 
Rosano, G., & Ceccarelli, E. (2014). Recombinant protein expression in Escherichia coli: 
advances and challenges. ​Frontiers In Microbiology​, ​5​(172), 1-17. 
http://dx.doi.org/10.3389/fmicb.2014.00172 
Siddiqui, M. (2010). Monoclonal antibodies as diagnostics; an appraisal. ​Indian Journal Of 
Pharmaceutical Sciences​, ​72​(1), 12. http://dx.doi.org/10.4103/0250-474x.62229 
Sitton, G., & Srienc, F. (2008). Growth dynamics of mammalian cells monitored with 
automated cell cycle staining and flow cytometry. ​Cytometry Part A​, ​73A​(6), 538-545. 
http://dx.doi.org/10.1002/cyto.a.20567 
        Therriault, J., & Evans, T. (2016). "Computational Design of Synthetic Antibodies for 
               Consumer Diagnostic Tests" ​Bioengineering Senior Theses. ​41. 
 
Torgersen, D., Mullin, N., & Drickamer, K. (1998). Mechanism of Ligand Binding to E- 
and P-selectin Analyzed Using Selectin/Mannose-binding Protein Chimeras. ​Journal Of 
Biological Chemistry​, ​273​(11), 6254-6261. http://dx.doi.org/10.1074/jbc.273.11.6254 
Umeda, A., Thibodeaux, G., Moncivais, K., Jiang, F., & Zhang, Z. (2010). A versatile 
approach to transform low-affinity peptides into protein probes with cotranslationally 
13 
 expressed chemical cross-linker. ​Analytical Biochemistry​, ​405​(1), 82-88. 
http://dx.doi.org/10.1016/j.ab.2010.05.026 
Umeda, A., Thibodeaux, G., Zhu, J., Lee, Y., & Zhang, Z. (2009). Site-specific Protein 
Cross-Linking with Genetically Incorporated 3,4-Dihydroxy-L-Phenylalanine. 
Chembiochem​, ​10​(8), 1302-1304. http://dx.doi.org/10.1002/cbic.200900127 
Veluraja, K., & Seethalakshmi, A. (2008). Dynamics of sialyl Lewis​a​ in aqueous solution 
and prediction of the structure of the sialyl Lewis​a​–SelectinE complex. ​Journal Of 
Theoretical Biology​, ​252​(1), 15-23. http://dx.doi.org/10.1016/j.jtbi.2007.12.024 
Wals, K., & Ovaa, H. (2014). Unnatural amino acid incorporation in E. coli: current and 
future applications in the design of therapeutic proteins. ​Frontiers In Chemistry​, ​2​. 
http://dx.doi.org/10.3389/fchem.2014.00015 
Wu, E., Zhou, S., Bhat, K., & Ma, Q. (2013). CA 19-9 and Pancreatic Cancer. ​Clinical 
Advances In Hematology & Oncology​, ​11​(1), 53-55. 
14 
